Serotonin, personality and borderline personality disorder

Acta Neuropsychiatrica

Volumn 14, Issue 2, 2002, Pages 66-70

  Hansenne, M ^a,b   Pitchot, W ^a   Ansseau, M ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Borderline personality disorder; Personality; Serotonin

Indexed keywords

FLESINOXAN; PROLACTIN; SEROTONIN;

ADULT; ARTICLE; BORDERLINE STATE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HORMONE RESPONSE; HUMAN; MALE; PROVOCATION TEST; SEROTONINERGIC SYSTEM;

EID: 0036062276     PISSN: 09242708     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1601-5215.2002.140203.x     Document Type: Article

References (36)

1. An alternative five-factor model for personality
2. A unified biosocial theory of personality and its role in the development of anxiety states
3. A psychobiological model of temperament and character
4. Serotonergic studies in patients with affective and personality disorders: Correlates with suicidal and impulsive aggressive behaviour
5. Serotonin function and self-injurious behaviour in personality disorder patients
6. A test of the tridimensional personality theory: Association with diagnosis and platelet imipramine binding in obsessive-compulsive disorder
7. Tridimensional personality questionnaire and serotonin in bulimia nervosa
8. Personality and cerebrospinal fluid monoamine metabolites in alcoholics and controls
9. The tridimensional questionnaire as a predictor of response to nefazodone treatment of depression
10. Neuroendocrine correlates of temperament traits in humans
11. The flesinoxan 5-HT1A receptor challenge in major depression and suicidal behaviour
12. Harm avoidance dimension of the tridimensional personality questionnaire (TPQ) and serotonin-1A activity in depressed patients
13. Temperament and character inventory (TCI) and depression
14. The tridimensional personality questionnaire in depression: State versus trait issues
15. Harm avoidance and serotonin
16. No association between the serotonin transporter gene regulatory region polymorphism and the tridimensional personality questionnaire (TPQ) temperament of harm avoidance
17. Association of a serotonin transporter gene promoter polymorphism with harm avoidance behaviour in an elderly population
18. 5-HT2a receptor polymorphism gene in bipolar disorder and harm avoidance personality trait
19. Fluoxetine in borderline personality disorder
20. Fluoxetine trial in borderline personality disorder
21. Fluoxetine in the treatment borderline and schizotypal personality disorders
22. Pharmacotherapy of impulsivity, agression and related disorders
23. Effect of fluoxetine on anger in symtopmatic volunteers with borderline personality disorder
24. Fluoxetine and impulsive agressive behaviour in personality-disordered subjects
25. An open trial of serlatrine in personality disordered patients with impulsive agression
26. An open trial of venlafaxine in borderline personality disorder
27. Borderline personality, impulsiveness, and platelet mo,oamine measures in bulimia nervosa and recurrent suicidal behaviour
28. 3H] paroxetine binding related to impulse suicide attemps and borderline personality disorder
29. Neuroendocrine study of serotonin function in female borderline personality disorder patients: A pilot study
30. A fenfluramine-activated FDG-PET study of borderline personality disorder
31. Serotonergic sensitivity in borderline personality disorder: Preliminary findings
32. m-Chlorophenylpiperazine challenge in borderline personality disorder: Relationship of neuroendocrine response, behavioural response, and clinical measures
33. Serotonin blunting to meta-Chlorophenylpiperazine (m-CCP) highly correlates with sustained chilhood abuse in impulsive and antoagressive female borderline patients